JP7042262B2 - 緑内障の治療のための、リポソームによって担持されるシチコリンを含む眼科用処方 - Google Patents

緑内障の治療のための、リポソームによって担持されるシチコリンを含む眼科用処方 Download PDF

Info

Publication number
JP7042262B2
JP7042262B2 JP2019520647A JP2019520647A JP7042262B2 JP 7042262 B2 JP7042262 B2 JP 7042262B2 JP 2019520647 A JP2019520647 A JP 2019520647A JP 2019520647 A JP2019520647 A JP 2019520647A JP 7042262 B2 JP7042262 B2 JP 7042262B2
Authority
JP
Japan
Prior art keywords
citicoline
composition
composition according
glaucoma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530729A (ja
JP2019530729A5 (https=
Inventor
ビルノ、クリスチアーノ
マリツィア、マルコ
Original Assignee
オミクロン イターリア エス．アール．エル．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オミクロン イターリア エス．アール．エル． filed Critical オミクロン イターリア エス．アール．エル．
Publication of JP2019530729A publication Critical patent/JP2019530729A/ja
Publication of JP2019530729A5 publication Critical patent/JP2019530729A5/ja
Application granted granted Critical
Publication of JP7042262B2 publication Critical patent/JP7042262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019520647A 2016-10-17 2017-10-16 緑内障の治療のための、リポソームによって担持されるシチコリンを含む眼科用処方 Active JP7042262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102016000103956A IT201600103956A1 (it) 2016-10-17 2016-10-17 Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
IT102016000103956 2016-10-17
PCT/IB2017/056400 WO2018073720A1 (en) 2016-10-17 2017-10-16 Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma

Publications (3)

Publication Number Publication Date
JP2019530729A JP2019530729A (ja) 2019-10-24
JP2019530729A5 JP2019530729A5 (https=) 2020-11-05
JP7042262B2 true JP7042262B2 (ja) 2022-03-25

Family

ID=58010202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520647A Active JP7042262B2 (ja) 2016-10-17 2017-10-16 緑内障の治療のための、リポソームによって担持されるシチコリンを含む眼科用処方

Country Status (9)

Country Link
US (1) US10576039B2 (https=)
EP (1) EP3525758B1 (https=)
JP (1) JP7042262B2 (https=)
EA (1) EA201990752A1 (https=)
ES (1) ES2987910T3 (https=)
IT (1) IT201600103956A1 (https=)
MX (1) MX388927B (https=)
TN (1) TN2019000112A1 (https=)
WO (1) WO2018073720A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3054066T3 (en) 2017-06-09 2026-01-29 Omnivision Gmbh Composition for the treatment of dry eye
IT201800005309A1 (it) * 2018-05-11 2019-11-11 Composizione ad attivita’ antimicrobica
CN110559261A (zh) * 2018-06-06 2019-12-13 常州药物研究所有限公司 含有纳米交联透明质酸的脂质体微乳及其制备方法和应用
CN111840220B (zh) * 2020-08-19 2022-09-30 开封康诺药业有限公司 一种胞磷胆碱钠注射液及其制备方法
MX2023013266A (es) * 2021-05-10 2023-12-15 Omikron Italia S R L Solucion oral basada en citicolina y nicotinamida para usar en el tratamiento del glaucoma.
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517421A (ja) 2009-02-11 2012-08-02 ライカ ラブズ リミテッド リポソームシチコリン注射薬
JP2013520406A (ja) 2010-02-22 2013-06-06 オミクロン イターリア エス．アール．エル． 緑内障及び高眼圧症の治療のためのシチコリン
JP2013532159A (ja) 2010-06-29 2013-08-15 ラボラトワール テア 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム
US20130216606A1 (en) 2010-08-12 2013-08-22 Singapore Health Services Pte Ltd Liposomal formulation for ocular drug delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114577A1 (en) * 1983-01-21 1984-08-01 MAGIS FARMACEUTICI S.p.A. New pharmaceutical composition
EP1334718A4 (en) * 2000-10-26 2007-07-18 Senju Pharma Co DRUG COMPOSITION CONTAINING DIPEPTIDYL ALDEHYDE COMPOUND
CN102078299B (zh) * 2011-01-04 2012-09-26 海南美大制药有限公司 胞磷胆碱钠脂质体固体制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517421A (ja) 2009-02-11 2012-08-02 ライカ ラブズ リミテッド リポソームシチコリン注射薬
JP2013520406A (ja) 2010-02-22 2013-06-06 オミクロン イターリア エス．アール．エル． 緑内障及び高眼圧症の治療のためのシチコリン
JP2013532159A (ja) 2010-06-29 2013-08-15 ラボラトワール テア 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム
US20130216606A1 (en) 2010-08-12 2013-08-22 Singapore Health Services Pte Ltd Liposomal formulation for ocular drug delivery

Also Published As

Publication number Publication date
JP2019530729A (ja) 2019-10-24
IT201600103956A1 (it) 2018-04-17
MX2019004463A (es) 2019-09-11
EP3525758B1 (en) 2024-05-22
MX388927B (es) 2025-03-20
US20190321292A1 (en) 2019-10-24
EP3525758C0 (en) 2024-05-22
TN2019000112A1 (en) 2020-10-05
EP3525758A1 (en) 2019-08-21
WO2018073720A1 (en) 2018-04-26
EA201990752A1 (ru) 2019-09-30
US10576039B2 (en) 2020-03-03
ES2987910T3 (es) 2024-11-18

Similar Documents

Publication Publication Date Title
JP7042262B2 (ja) 緑内障の治療のための、リポソームによって担持されるシチコリンを含む眼科用処方
EP2538918B1 (en) Citicoline for the treatment of glaucoma
JP5959507B2 (ja) 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン
KR20130082069A (ko) 안과 및 수의 안과에서 사용하기 위한 약학적 조성물
JP2019142907A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
WO2012073077A1 (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
US20130245126A1 (en) Geranylgeranylacetone formulations and retinal delivery thereof
EP0063973B1 (fr) Composition pour collyre à base de sulfate de chondroitine A
TW202023529A (zh) 緩釋眼用藥物組合物及其用途
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
CN110269839A (zh) 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用
US20200121616A1 (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CA3202461A1 (en) Dicarboxylic acid esters for inducing an analgesic effect
CN115568282A (zh) 抗衰老糖肽治疗干眼症、视网膜退行性疾病或眼部炎症的用途
JPH05501714A (ja) リポソーム組成物
US20140187646A1 (en) Geranylgeranylacetone formulations and retinal and systemic delivery thereof
US20140194527A1 (en) Geranylgeranylacetone formulations and retinal delivery thereof
US20240261311A1 (en) Methods of treating or preventing allergies and chronic nasal congestion
ES2577885B1 (es) Composición de doxiciclina en liposomas para la prevención, mejora y/o tratamiento de patologías oculares.
RU2733392C1 (ru) Комбинированное офтальмологическое средство
Garrigue et al. A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models
JPH10203979A (ja) チアプロフェン酸を含有する抗眼炎症剤
CN104906037A (zh) 一种重组水蛭素滴眼液及其制备方法
OA21266A (en) Dicarboxylic acid esters for inducing an analgesic effect.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220314

R150 Certificate of patent or registration of utility model

Ref document number: 7042262

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250